Daniel Cruz, MD
Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1427090091
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,700 of the $2,630 with a category attached, or 64.6%. W. L. Gore & Associates, Inc. accounts for 64.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,700 and has fallen 81.5% since, to $314 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 9 payments — averaging $292.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$2K
- Cvrx, Inc.$353
- Abbott$263
- Edwards Lifesciences$172
- Endotronix, Inc.$142
What the payments were for
- Speaking & faculty fees$1,70065%
- Food & beverage$93035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 3 | $1,700 |
| Cvrx, Inc. | 2 | $353 |
| Abbott | 2 | $263 |
| Edwards Lifesciences | 1 | $172 |
| Endotronix, Inc. | 1 | $142 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,630 in reported general payments places this provider in the 30th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 151 | $4,588,397 |
| EntrestoSacubitril/Valsartan | 330 | $375,038 |
| EliquisApixaban | 345 | $373,808 |
| FarxigaDapagliflozin Propanediol | 171 | $188,183 |
| JardianceEmpagliflozin | 157 | $140,679 |
| XareltoRivaroxaban | 60 | $63,614 |
| Repatha SureclickEvolocumab | 33 | $26,398 |
| BrilintaTicagrelor | 34 | $16,509 |
| Repatha SyringeEvolocumab | 11 | $10,338 |
| CorlanorIvabradine Hcl | 13 | $9,127 |
| Potassium Chloride | 214 | $8,137 |
| Metoprolol Succinate | 422 | $7,461 |
| Rosuvastatin Calcium | 425 | $6,814 |
| Sildenafil Citrate | 18 | $5,615 |
| Ezetimibe | 139 | $5,105 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Los Angeles
- Eugene DepasqualeLos Angeles$104K
- Joseph RahmanLos Angeles$101K
- Jon KobashigawaLos Angeles$54K
- Ajay VaidyaLos Angeles$17K
- Aaron WolfsonLos Angeles$16K
- Michael FongLos Angeles$9K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.